Aprea Therapeutics Inc. (APRE)
NASDAQ: APRE
· Real-Time Price · USD
1.66
-0.11 (-6.09%)
At close: Jun 20, 2025, 3:59 PM
1.64
-1.51%
After-hours: Jun 20, 2025, 04:00 PM EDT
-6.09% (1D)
Bid | 1.62 |
Market Cap | 9.18M |
Revenue (ttm) | 767.39K |
Net Income (ttm) | -14.08M |
EPS (ttm) | -2.34 |
PE Ratio (ttm) | -0.71 |
Forward PE | -1.21 |
Analyst | Buy |
Ask | 1.92 |
Volume | 29,956 |
Avg. Volume (20D) | 27,675 |
Open | 1.75 |
Previous Close | 1.77 |
Day's Range | 1.62 - 1.76 |
52-Week Range | 1.41 - 5.01 |
Beta | 1.61 |
About APRE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol APRE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for APRE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+17.65%
Aprea Therapeutics shares are trading higher on co...
Unlock content with
Pro Subscription
3 months ago
+9.87%
Aprea Therapeutics shares are trading higher after the company announced it entered a medical transfer agreement with MD Anderson Cancer Center to explore APR-105 as a potential treatment for head and neck squamous cell carcinoma.